Teva Pharmaceuticals and IBM Partner to Build Global
e-Health Solutions on the IBM Watson Health Cloud
Collaboration Plans to Commercialize Solutions for Deployment Worldwide
Jerusalem and Cambridge, Mass., September 10, 2015: IBM (NYSE: IBM) Watson Health and Teva
Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Teva has been selected as
its first Foundational Life Sciences Partner for the Watson Health Cloud. As part of this new
strategic partnership, Teva becomes the first global pharmaceutical company to tap the power of the
Watson Health Cloud to benefit patients and healthcare providers across geographies.
Teva has chosen the IBM Watson Health Cloud as a preferred global technology platform and aims to
build solutions designed to help millions of individuals worldwide with complex and chronic
conditions such as asthma, pain, migraine and neurodegenerative diseases. In addition, a joint
Teva-IBM Research team will deploy Big Data and machine learning technology to create disease
models and advanced therapeutic solutions.
“Teva is actively exploring the e-health evolution with a strong focus on fulfilling unmet and
emerging patients’ needs. The IBM Watson Health Cloud provides a strong foundation on which we can
realize this vision,” said Guy Hadari, SVP and CIO for Teva Pharmaceutical Industries Ltd. “By
building on the Watson Health Cloud, we believe Teva will be in a unique position to put the best
information and insights in the hands of physicians, care teams and patients, to empower treatment
optimization for individuals and populations across the spectrum of acute and chronic conditions.
Watson holds promise to provide Teva with better insights, real-time feedback and options for
clinicians to consider to improve patient care.”
Watson is a groundbreaking cognitive computing platform that represents a new era of computing
based on its ability to interact in natural language, process vast amounts of Big Data to uncover
patterns and insights, and learn from each interaction. The Watson Health Cloud provides an open
development platform for physicians, researchers, insurers and companies focused on creating health
and wellness solutions.
Teva will work with IBM on long-range platform and solutions development, with experts
collaborating to enhance IBM Watson Health Cloud capabilities and explore synergies with existing
Watson Health ecosystem partners. The company, which has one of the world’s largest portfolios of
medicines, expects to develop solutions designed to collect and analyze real world evidence, draw
powerful insights and inform a variety of initiatives such as reducing drug misuse or increasing
prescribed medication adherence.
“Teva’s pioneering digital health vision, reach across global markets, extensive portfolio of
medicines and significant industry experience make them a preferred life science ecosystem partner
for the Watson Health Cloud,” said Mike Rhodin, senior vice president, IBM Watson Group.
IBM’s Global Business Services will work closely with a Teva Analytics team to assess the data and
the analytics model requirements for the Real World Evidence e-health solution.
IBM Watson: Pioneering a New Era of Computing
Watson is the first commercially available cognitive computing capability representing a new era in
computing. The system, delivered through the cloud, analyzes high volumes of data and complex
questions posed in natural language and proposes evidence-based answers. Watson is continuously
gaining in value and knowledge over time, from previous interactions.
In January 2014, IBM launched the IBM Watson unit, a business dedicated to developing and
commercializing cloud-delivered cognitive computing technologies. The move signified a strategic
shift by IBM to deliver a new class of software, services and apps that improves by learning, and
discovers insights from massive amounts of Big Data. As part of the unit, the company has
increased the number and diversity of cognitive computing services delivered to its partners,
adding new beta Watson services in February 2015, and scalable deep learning APIs with the
acquisition of AlchemyAPI in March 2015.
In April 2015, the company continued to build on its strengths in cognitive computing, analytics,
security and cloud with the launch of IBM Watson Health and the Watson Health Cloud platform. The
new unit will help improve the ability of doctors, researchers and insurers to innovate by
surfacing new insights from the massive amount of personal health data being created daily. The
Watson Health Cloud allows this information to be anonymized, shared and combined with a dynamic
and constantly growing aggregated view of clinical, research and social health data that clients
choose to share.
About IBM
For more information on IBM Watson, visit: ibm.com/watson. For more information on IBM Watson
Health, visit: ibm.com/watsonhealth
Check out the IBM Watson press kit at: http://www-03.ibm.com/press/us/en/presskit/27297.wss
Join the conversation at #ibmwatson and #watsonhealth. Follow Watson on Facebook and see Watson on
YouTube and Flickr.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical
company that delivers high-quality, patient-centric healthcare solutions to millions of patients
everly day. Headquartered in Israel, Teva is the world’s largest generic medicines producer,
leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products
in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system, including pain, as well as a
strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities
in its global research and development division to create new ways of addressing unmet patient
needs by combining drug development capabilities with devices, services and technologies. Teva’s
net revenues in 2014 amounted to $20.3 billion. For more information, visit
www.tevapharm.com.
###
Teva’s Safe Harbor Statement
This release contains forward-looking statements, which are based on management’s current
beliefs and expectations and involve a number of known and unknown risks and uncertainties
that could cause our future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such differences include risks
relating to: our ability to develop and commercialize additional pharmaceutical products;
competition for our innovative products, especially Copaxone® (including competition from
orally-administered alternatives, as well as from potential purported generic equivalents) and
our ability to migrate users to our 40 mg/mL version; the possibility of material fines,
penalties and other sanctions and other adverse consequences arising out of our ongoing FCPA
investigations and related matters; our ability to achieve expected results from the research
and development efforts invested in our pipeline of specialty and other products; our ability
to reduce operating expenses to the extent and during the timeframe intended by our cost
reduction program; our ability to identify and successfully bid for suitable acquisition
targets or licensing opportunities, or to consummate and integrate acquisitions; the extent to
which any manufacturing or quality control problems damage our reputation for quality
production and require costly remediation; increased government scrutiny in both the U.S. and
Europe of our patent settlement agreements; our exposure to currency fluctuations and
restrictions as well as credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property rights of our specialty
medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; governmental investigations into sales and marketing practices,
particularly for our specialty pharmaceutical products; adverse effects of political or
economic instability, major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with internal or third-party
information technology systems that adversely affect our complex manufacturing processes;
significant disruptions of our information technology systems or breaches of our data
security; competition for our generic products, both from other pharmaceutical companies and
as a result of increased governmental pricing pressures; competition for our specialty
pharmaceutical businesses from companies with greater resources and capabilities; the impact
of continuing consolidation of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic products; potential liability in
the U.S., Europe and other markets for sales of generic products prior to a final resolution
of outstanding patent litigation; our potential exposure to product liability claims that are
not covered by insurance; any failure to recruit or retain key personnel, or to attract
additional executive and managerial talent; any failures to comply with complex Medicare and
Medicaid reporting and payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the effects of increased
leverage and our resulting reliance on access to the capital markets; potentially significant
increases in tax liabilities; the effect on our overall effective tax rate of the termination
or expiration of governmental programs or tax benefits, or of a change in our business;
variations in patent laws that may adversely affect our ability to manufacture our products in
the most efficient manner; environmental risks; and other factors that are discussed in our
Annual Report on Form 20-F for the year ended December 31, 2014 and in our other filings with
the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the
date on which they are made and we assume no obligation to update or revise any
forward-looking statement, whether as a result of new information, future events or otherwise.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024
